

Mitigating Cancer-Related Cognitive Impairment in Older Adults with Breast Cancer Receiving Chemotherapy: Memory and Attention Adaptation Training-Geriatrics (MAAT-G): A randomized pilot study

WILMOT CANCER INSTITUTE – UNIVERSITY OF ROCHESTER MEDICAL CENTER:

Study Chair:

Allison Magnuson, DO

James P Wilmot Cancer Center
601 Elmwood Ave, Box 704
Rochester, NY 14642
Phone: (585) 275-7246/ Fax: 273-1042
Allison_Magnuson@URMC.Rochester.edu

Study Co-Investigators:

Supriya G. Mohile, MD, MS

James P Wilmot Cancer Center
601 Elmwood Ave, Box 704
Rochester, NY 14642
Phone: 585-273-4150/ Fax: 273-1042
Supriya_Mohile@urmc.rochester.edu

Michelle Janelins, PhD

James P Wilmot Cancer Center
601 Elmwood Ave
Rochester, NY 14620
Michelle_Janelins@urmc.rochester.edu

Lauren DeCaporale, PhD

Dept of Surgery, Strong Memorial Hospital
601 Elmwood Ave
Rochester, NY 14620
Lauren_Decaporale@URMC.Rochester.edu

Jeremy Kelly, PhD

Dept of Surgery, Strong Memorial Hospital
601 Elmwood Ave
Rochester, NY 14620
Jeremy_Kelly@URMC.Rochester.edu

Lee Kehoe, PhD, MS, LMHC
James P Wilmot Cancer Center
601 Elmwood Ave
Rochester, NY 14642
Lee_Kehoe@URMC.Rochester.edu

Kim Parkhurst
Dept of Surgery, Strong Memorial Hospital
601 Elmwood Ave
Rochester, NY 14620

Jason Zittel, MD
Myers Cancer Center
111 Clara Barton Street
Dansville, NY 14437
Phone: 585-335-6830
Jason_Zittel@URMC.Rochester.edu

Study Personnel:

Terri Lloyd
James P Wilmot Cancer Center
601 Elmwood Ave, Box 704
Rochester, NY 14642
Phone: (585) 276-5652/ Fax: 273-1042
Terri1_Lloyd@URMC.Rochester.edu

Jessica Bauer
James P Wilmot Cancer Center
601 Elmwood Ave, Box 704
Rochester, NY 14642
Phone: (585) 276-5652/ Fax: 273-1042
JessicaC_Bauer@urmc.rochester.edu

Megan Wells
James P Wilmot Cancer Center
601 Elmwood Ave, Box 704
Rochester, NY 14642
Phone: 585- 275-8273/ Fax: 273-1042
Megan_Mckillip@urmc.rochester.edu

Carrie Sylor, RN

Myers Cancer Center
111 Clara Barton Street
Dansville, NY 14437
Phone: 585-335-6830
Carrie_Sylor@urmc.rochester.edu

Heidi D'Aurizio, RN

James P Wilmot Cancer Center
601 Elmwood Ave, Box 704
Rochester, NY 14642
Phone: 585-273-4150/ Fax: 273-1042
Heidi_DAurizio@URMC.Rochester.edu


Lucia Berkoff

James P Wilmot Cancer Center
601 Elmwood Ave, Box 704
Rochester, NY 14642
Phone: 585- 275-8273/ Fax: 273-1042

TABLE OF CONTENTS:

1.0 Study Schema and Abstract.....	5
2.0 Specific Aims	6
3.0 Background.....	7
4.0 Subject Eligibility.....	10
5.0 Recruitment and Consent	11
6.0 Registration & Randomization	13
7.0 Treatment Protocol	14
8.0 Data Management	18
9.0 Data Safety and Monitoring.....	21
10.0 References	24

1.0 STUDY SCHEMA



2.0 SPECIFIC AIMS

Cancer-related cognitive dysfunction (CRCDD) is a significant problem. Our group and others have demonstrated that CRCDD affects up to 75% of patients during treatment and can create difficulties in attention, processing speed, executive function and memory.¹⁻³ Older adults are at greater risk of developing CRCDD;⁴⁻⁸ half of women aged ≥ 65 receiving adjuvant chemotherapy for breast cancer report worsening of cognition, and 25% have measurable declines on neuropsychological testing six months post-chemotherapy.^{9,10} Patients with localized breast cancer have excellent overall survival but are at risk for CRCDD as a long-term side effect of therapy.¹¹⁻¹³ For older adults, CRCDD can compromise functional independence (e.g. Instrumental Activities of Daily Living [IADL]).¹⁴ The etiology of CRCDD likely involves multiple factors including host factors (e.g. age, cognitive reserve), biologic factors (e.g. cortisol-mediated stress response), clinical factors (e.g. comorbidities) and psychological factors (e.g. coping mechanisms).^{2,15-20} While alleviating or preventing CRCDD is important to older adult patients and their caregivers, interventions tailored to them do not exist.²¹

Memory and Attention Adaptation Training-Geriatrics (MAAT-G) is a cognitive behavioral therapy-based intervention for targeting modifiable factors of CRCDD for older adults.²⁰⁻²³ MAAT-G provides instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies for episodes of cognitive failure (e.g. lapses in memory, attention). MAAT-G is derived from an existing CRCDD intervention (MAAT), and was adapted for the unique needs of older adults. MAAT-G is a series of ten manualized workshops delivered by a trained clinician (e.g. psychologist, psychology post-doctoral fellow, psychology intern or Research Nurse) via video-conferencing combined with a participant workbook. In younger cancer survivors (i.e. those who have completed chemotherapy), the original MAAT intervention was shown to improve self-perceived cognition (Functional Assessment of Cancer Therapy–Cognition [FACT-Cog], $d=0.52$), verbal memory (California Verbal Learning Test 2 [CVLT], $d=-0.63$) and processing speed (Symbol Digit Subtest of Telephone Based Neuropsychological Status [TBANS], $d=0.5$).^{11,26} These cognitive functions are particularly important for older adults; and we propose to deliver MAAT-G alongside systemic cancer therapy to mitigate the development of CRCDD (when risk is highest) and CRCDD-related effects on functional independence for older adults.

Study Objective:

Primary Objective:

- Examine the preliminary effect of MAAT-G on FACT-Cog.
 - Hypothesis: Patients receiving MAAT-G will have better perceived cognition (FACT-Cog) compared to control at follow-up.

Secondary Objectives:

- Estimate MAAT-G's effect on function (e.g. IADL) and objective neuropsychological measures including CANTAB, FACT-Cog, COWA, HVLT-R, GDS, Brief Test of Adult Cognition by Telephone (BTACT), and GAD-7.
 - Hypothesis: Patients receiving MAAT-G will have better short-term visual/spatial memory, sustained attention, visual memory/new learning, verbal fluency, verbal learning and memory, and function compared to control at follow-up.
- Develop a more complete understanding of the patient and caregiver experience with MAAT-G and their perceptions of MAAT-G's benefits on cognition and function beyond what is captured by quantitative measures alone, through integration of quantitative

data with semi-structured interviews.

3.0 BACKGROUND AND RATIONALE

3.1. Cancer-related cognitive dysfunction (CRCDD) is a prevalent clinical problem; older adults are at greater risk of experiencing CRCDD with cancer treatment, especially chemotherapy.^{1-8,15,29,30} Symptoms of CRCDD include problems with memory, attention and executive function.² CRCDD is common; in the largest CRCDD study to date, patients with breast cancer receiving adjuvant chemotherapy reported significantly greater cognitive difficulties from pre-chemotherapy to 6 months post-chemotherapy, compared to age-matched controls (mean change FACT-Cog score -10.4 in patients versus mean change +1.5 in controls).^{1,2,15} Older patients, particularly those with lower cognitive reserve, may be most vulnerable to the effects of chemotherapy on cognition.^{4-6,29,30} Ahles and colleagues observed that the subgroup of older patients with low baseline cognitive reserve prior to adjuvant chemotherapy for breast cancer had the largest decline in processing speed post-treatment.⁴ Twenty-five percent of older women with breast cancer receiving chemotherapy develop cognitive decline from pre- to six months post-chemotherapy (defined as decline in 1 standard deviation in \geq two neuropsychological domains)¹⁰, and half report worsening of their cognition.⁹ The effects of CRCDD can be long-term; up to 35% report CRCDD months to years after completing therapy; cross-sectional studies of older breast cancer survivors demonstrate lower performance in multiple areas of neurocognitive function compared to age-matched controls without cancer, even several years after treatment.^{12,13}

3.2. Advances in breast cancer therapies have greatly improved survival rates; older patients are living long enough to experience long-term complications of treatment such as CRCDD. The five-year overall survival rate for patients with early stage breast cancer (I-III) is 98.9% for localized disease (breast only) and 85.2% for regional disease (lymph node involvement).¹¹ Given these favorable cancer-related outcomes, CRCDD and its functional consequences are particularly relevant for older adults with breast cancer. CRCDD may create difficulties with Instrumental Activities of Daily Living (IADL), such as managing medications, which may compromise independence and quality of life for older adults.^{7,14,31-33} Nearly one-third of older women receiving adjuvant chemotherapy for breast cancer experience functional decline 1 year post-treatment.³⁴ Despite this vulnerability, there are no available interventions to mitigate CRCDD for older adults, because older adults are underrepresented in oncology clinical trials, and interventions to improve issues that are important to older adults, such as cognition, are not prioritized.³⁵⁻³⁷ A geriatric oncology U13 conference series supported by the NIA, NCI, and CARG highlighted intervention development, particularly cognitive interventions, as a high priority area for research.^{22,24,25,38,39}

3.3. Multiple factors are likely involved in the etiology of CRCDD including host factors (e.g. age, cognitive reserve), biologic factors (e.g. cortisol-mediated stress response), clinical factors (e.g. comorbidities) and psychological factors (e.g. coping mechanisms).^{2,15-20} CRCDD can be conceptualized using a diathesis stress model, whereas under routine and low stress conditions, cognitive failures of daily life (e.g. mental lapses in memory, attention) are likely to occur with less frequency and when they do, they are readily managed.²⁸ However, under periods of sustained physical and psychological stress (allostatic overload) such as chemotherapy, there may be dysregulation of the stress response leading to more frequent cognitive failures.¹⁹ The threshold for allostatic overload is variable and depends on an individual's self-regulatory capacity (i.e. an individual's limited fund of "mental energy" to attend to self-regulatory behaviors such as decision-making, attentional demands, and emotional regulation).^{40,41} Coping involves monitoring self-regulatory capacity and recognizing situations of allostatic overload that require adjustment/adaptation of behaviors.²⁰ Maladaptive coping mechanisms can lead to further negative effects on cognition.⁴² Additionally, individuals possess varying abilities to compensate for

cognitive stressors; however, compensatory strategies can be taught.

Memory and Attention Adaptation Training-Geriatrics (MAAT-G) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT-G focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD, and provides instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies. MAAT-G was adapted from the original MAAT intervention²⁰⁻²² by the study team using the Contextual, Cohort-based, Maturity, Specific Challenge (CCMSC) model to account for the unique needs of older adults. The original MAAT intervention was evaluated in three separate studies of younger breast cancer survivors (n=29-47; mean age ranging 50-56 years) and improved perceived cognition (Functional Assessment of Chemotherapy-Cognition [FACT-Cog]) compared to active controls (p=0.02, d=0.52). We believe the compensatory strategy approach is advantageous to the retraining approach as it may be completed in a shorter format better suited to adult survivors. It overlaps with theoretical principals of CBT; learning new behaviors and cognitions to promote therapeutic, adaptive change. Compensatory strategies used in MAAT-G include self-awareness training (self-monitoring record keeping to identify "at risk" situations where cognitive failures may occur), Self-Instructional Training (SIT), or a method of "self-talk" to enhance on-task attention, mnemonic strategies to enhance retention and retrieval for daily working memory, and organizational and social skills training such as keeping a simplified schedule or active listening skills. Self-regulation skills of applied relaxation training and activity scheduling/pacing are also included. The overarching aim of MAAT-G is to enhance self-management and coping with cognitive failures in daily life to minimize impact on quality of life and **to mitigate CRCD and its consequences for older adults with breast cancer.**

3.4. The **scientific premise** of this new research is that CRCD is a significant problem, particularly for older adults, and interventions to improve cognitive outcomes are needed.

3.6 Preliminary Studies:

3.6a. Older patients and caregivers are concerned about the cognitive effects of chemotherapy. We conducted pilot work exploring goals with patients and caregivers in the SOCARE clinic. Patients and caregivers rated their goal to preserve cognition as high as cancer-related outcomes (e.g. improved survival) in the decision-making process for cancer treatment.²¹

3.6b. Nearly half of patients with breast cancer receiving adjuvant chemotherapy report a clinically significant decline in self-reported cognition.¹ Additionally, in this population frailty characteristics increased from pre- to post-chemotherapy; and importantly patients with worse perceived cognition at baseline had a greater number of frailty characteristics after chemotherapy.⁴⁷

3.6c. It is feasible to study behavioral interventions in clinical trials for older adults with cancer receiving chemotherapy.⁴⁸ A pilot RCT testing the feasibility of implementing GA-guided management interventions for older adults with cancer receiving chemotherapy was conducted by the PI at the University of Rochester Wilmot Cancer Institute. 71 older adults were enrolled (75% of approached patients consented); 89% completed the 3-month follow-up assessment. A subset of older adults receiving chemotherapy experienced cognitive decline; in analysis of the Clock Draw Test, 15% demonstrated significant decline at 6-week follow-up.

3.6d. MAAT was pilot-tested in three separate studies of younger breast cancer survivors (n=29-47; mean age ranging 50-56 years).^{11,26,27} Overall, MAAT improved perceived cognition (Functional Assessment of Chemotherapy-Cognition [FACT-Cog]) compared to active controls (p=0.02, d=0.52). For objective neurocognitive outcomes, MAAT participants demonstrated improved verbal memory (California Verbal Learning Test [CVLT]-2, p<0.05, d=-0.63) and processing speed compared to controls (Symbol Digit subtest of Telephone-Based Assessment of Neuropsychological Status [TBANS], p=0.03, d=0.5).²⁶ Specifically, the original MAAT program was brief and consisted of 4 (30-50 minute) office visits and 3 phone contacts. This was tested in pilot research using a single-arm study. Twenty-nine breast cancer survivors (average 8.2 years post-chemotherapy; SD = 4.4 years) completed MAAT. Principal outcome measures included self-reported cognitive function in daily life as assessed by The Multiple Ability Self-Report Questionnaire (MASQ) Quality of Life- Cancer Survivors scale, satisfaction ratings and a brief neuropsychological test battery. Testing occurred at 4 time points: baseline, post-treatment, 2-month and 6-month follow-up. Results indicated a significant reduction in self-reported daily cognitive complaints (MASQ), improved quality of life and high satisfaction ratings. Neuropsychological test score improvements were observed in tests of verbal memory and in processing speed. Finally, survivors reported high satisfaction with MAAT. The one-group design limited conclusions about efficacy and the effect of practice on repeat administration of neuropsychological tests, but pilot results warranted further MAAT study.

In a second study utilizing a wait-list control design, 40 women were enrolled and randomized to treatment (n = 19) or waitlist control (n = 21) conditions and assessed at baseline, post-treatment and 3 month follow-up time points. ANCOVA demonstrated two statistically significant outcomes controlling for effects of education and IQ: 1) the spiritual wellbeing subscale of the Quality of Life-Cancer Survivor Scale (QOL-CS); and 2) CVLT-2 Total Score. Effect size in verbal memory performance (CVLT-2 Total Score) among MAAT participants was large at post treatment even after subtracting the effect size observed in controls (.50).

In a third study, MAAT was delivered via televideo conferencing and patients were randomized to receive the MAAT intervention versus supportive therapy (control). One method of improving access to rural cancer survivorship services is through communications technologies. “Telehealth” refers to the use of a broad array of communications devices to improve health care access.

3.6e. Our team has adapted the MAAT intervention specifically for use in older adults through collaboration with key stakeholders: To refine and adapt MAAT for older adults, I used the Contextual, Cohort-based, Maturity, Specific Challenge (CCMSC) model for adapting CBT- based interventions for older adults.³⁹ The model is informed by aging research and accounts for the social context of older adults.³⁹ Subsequently, I made further refinements to MAAT-G using feedback from key stakeholders through a series of focus groups with members of SCOREboard, our older adult patient advisory group. SCOREboard members reviewed and provided feedback on workshop content, relevance to older adults, optimizing feasibility for delivering workshops concurrent with cancer treatment, and aspects related to technology support for older adults (see **Table 1** for details of MAAT-G adaptations).

3.6f. The usability of MAAT-G is currently being evaluated in four older adults receiving systemic treatment for breast cancer at the time of this submission.

Regarding recruitment to the usability study, 4/4 approached patients consented to the study (100% consent rate). The mean age of patients enrolled is 73.3 (range 67-77). Educational background varied; one patient has less than high school degree, two have some college education and one has graduate level education. The usability phase trial also enrolls caregivers if they are identified; 1 of the 4 patients identified a caregiver and this caregiver consented to

enrollment. There was 100% capture of baseline assessment measures; these measures included perceived and objective cognitive assessment as well as selected geriatric assessment measures of functional independence and psychological status. All four patients remain on study and to date have completed MAAT-G workshops on schedule (at time of submission, two patients have completed 9/10 workshops, one patient has completed 8/10 and one patient has completed 6/10).

Table 1: MAAT-G Adaptations Using CCMSC Model

CCMSC Model Component and Goal	Example of Adaptations Incorporated into the MAAT-G intervention through the CCMSC model and stakeholder feedback
Social Context Factors: Appreciate that older adults may have distinctive social context, including specific environments (e.g. age-segregated housing, aging services networks).	<ol style="list-style-type: none"> 1. A section was added to the clinician's manual to educate clinicians on social context factors and how this may influence compensatory strategies for older adults. 2. A screening question was added to the clinician's manual to inquire about social supports to encourage clinicians, patients and caregivers to consider all available resources for compensatory strategies.
Cohort-based Considerations: Understand that membership in a birth-defined group may impact abilities, beliefs, attitudes and personality.	<ol style="list-style-type: none"> 1. A section was incorporated into the clinician's manual to educate on cohort-based factors and how this may influence coping mechanisms and stress response. 2. The patient workbook was adapted throughout to minimize complex terminology to account for potentially lower education levels of older cohorts. 3. Examples of scenarios of cognitive overload were adjusted throughout the manual (e.g. references to job-type examples were changed to more social-based examples of working tasks that might be more consistent with activities of older adults who may be retired) 4. Technology support materials were developed to encourage inclusion of patients with limited technology background
Consider Aspects Related to Maturity Factors: Appreciate cognitive strengths of older adults but understand that some may have pre-existing cognitive impairment. Appreciate influence of previous life experiences on emotional responses.	<ol style="list-style-type: none"> 1. A section was added to the clinician's manual to educate clinicians on maturity factors and its effect on pace of information receipt, coping mechanisms and stress response. 2. MAAT-G was extended to 10 workshop sessions (from 8) to decrease the amount of new material presented during each workshop session. 3. Complexity of examples presented in the workshop sessions was reduced. 4. Font type and sizing was adjusted in the workbook to accommodate for potential visual impairment.
Acknowledge Specific Challenges: Appreciate how symptoms and comorbidities can impact psychosocial function.	<ol style="list-style-type: none"> 1. A step was added to the clinician manual to screen for hearing loss to allow clinician to proactively adapt volume and rate of speech while delivering intervention. 2. Information about volume control highlighted in the technology support manual for patients. 3. Font type and sizing was adjusted in the workbook to accommodate potential visual impairment.

4.0 SUBJECT ELIGIBILITY

The eligibility criteria are aimed at identifying older patients undergoing cancer treatment. As above, if patients are able and willing to identify a caregiver, caregivers will also be consented to participate in study processes.

4.1. Patient Inclusion Criteria:

- Have a diagnosis of invasive breastcancer
- Planned to receive systemic therapy for breast cancer or actively receiving systemic therapy for breast cancer with two additional cyclesremaining.
- Be age 65 or older
- Able to provide informed consent (or possess a designated health care proxy that can do the same that was designated prior to the patient losing decision-making capabilities)
- Able to read and understand English (or possess a designated health care proxy that can do the same that was designated prior to the patient losing decision-making capabilities)

4.2. Patient Exclusion Criteria:

- Have surgery planned within 3 months of consent
- Patients who do not have decision-making capacity (decisionally or cognitively impaired) **AND** do **NOT** have a previously designated health care proxy (established prior to their cognitive impairment) available to sign consent
- Patients with breast cancer receiving endocrine therapy as their only systemic therapy will not be eligible.

We anticipate enrolling 85 patients to phase II over a 24-36 month timeframe.

4.3 Entry criteria for caregivers:

A caregiver can be anyone, age 21 or over, who is able to understand spoken English, understand the study process and provide informed consent. One caregiver for each patient will be eligible and must be chosen by the patient. For the purposes of this study, a caregiver is defined as a valued and trusted person in a patient's life who is supportive in health care matters by providing valuable social support and/or direct assistive care.

4.3.1. Inclusion criteria for caregivers:

- Selected by the patient when asked if there is a "family member, partner, friend or caregiver [age 21 or older] with whom you discuss or who can be helpful in health-related matters;" patients who cannot identify such a person ("caregiver") will remain eligible for the study.

4.3.2 Exclusion criteria for caregivers

- Caregivers unable to understand the consent form due to cognitive, health or sensory impairment will be excluded

5.0 IDENTIFICATION, RECRUITMENT, AND CONSENT PROCEDURES

Subjects will be enrolled at the University of Rochester Comprehensive Breast Cancer Center at Pluta Cancer Center, the University of Rochester Wilmot Cancer Institute at Highland Hospital, and Myers Cancer Center in Dansville. Patients will be recruited from the breast medical oncology clinics at these three sites. The clinic schedules of breast oncologists and their advanced practice providers (APPs) will be screened for eligible patients.

To ensure appropriate safety precautions when conducting in-person study procedures, the process for conducting in-person visits outlined in the Guidance for Human Subject Research will be followed.

5.1. Patient and Caregiver Identification, Recruitment, and Consent Procedures:

Potential patients will be identified in multiple ways. First, at the three sites for accrual, study participants will be identified by their treating physician, the nurses that work with the physicians, and the study coordinator. The study coordinator works closely with the physicians and nurses to monitor patients and identify those patients that are anticipated to begin cancer treatment. With permission from oncology providers, we will screen for eligible patients from clinic schedules. The study coordinator contacts the

physician (or their designee) and lets them know that a patient may be eligible for the study. The physician (or their designee) then confirms if the patient is a good study candidate or not and affirms that the patient has decision making capacity. If there is a question about eligibility, the principal investigator will be contacted and will meet with the patient and/or health care proxies, review the medical records, and perform an assessment of eligibility if necessary. After meeting with the physician (or their designee), the study coordinator will meet with the patient, and explain the details of the study. Study staff will introduce the study to the patients and provide adequate time to read the consent.

For patients at the Dansville location, the study coordinator will contact the physician (or their designee) to let them know that a patient may be eligible for the study. The physician then confirms if the patient is a good study candidate or not and affirms that the patient has decision making capacity. The physician or a member of the study team then mentions the study to the patient during the visit. If the patient expresses interest, a member of the study team will consent the patient and provide the patient with the necessary materials to participate in the study. If the patient would like to consider the study further, the study team at Myers Cancer Center (Dansville) can provide the patient with an informational consent and with their permission, a member of the MAAT-G study team will contact the patient at a later date to follow-up.

Recruitment of caregivers: If patients are agreeable to participating in the study, patients will be asked if there is a “family member, partner, friend or caregiver [age 21 or older] with whom you discuss or who can be helpful in health-related matters;” to participate as a caregiver. If patients are unable to identify a caregiver, they will still be able to participate. If patients are able to identify a caregiver, a member of the study team will give the patient a contact form that summarizes the purpose of the study, what the study would entail for the caregiver, and study coordinator’s contact information. If the caregiver is interested in participating, s/he will contact the study coordinator using the contact information provided on the contact form. The study coordinator is not allowed to initiate the first point of contact with the caregiver.

5.1.1. Informed Consent: Informed consent will be obtained from the patient by a member of the study team in person during a clinic visit. The member of the study team uses the informed consent document as a written aid and goes over every detail of the study with the patient and/or health care proxy in person and recruits them to the study. Members of the study team are available to answer any questions the patient may have about any aspect of the study prior to consenting and throughout the entire study period. Patients may choose to sign the informed consent immediately on the day the study information is presented to them or they may choose to take the informational consent form home and discuss it with others. If they want to participate in the study, they can sign it the next time they meet with a member of the study team. If the patient is participating in a telehealth visit and expresses interest, the coordinator will ask patient for his/her permission to be mailed an informational consent for their review. The coordinator will then follow up with the patient by phone or in person a few days later to answer any questions and to see if the patient is willing to participate in the study. If the patient would like to participate in the study, the member of the study team will either meet with the patient in person to have the consent form signed, or the coordinator will complete a verbal informed consent with the patient over the phone. See 5.1.2.

5.1.2. Verbal Informed Consent: If the patient or caregiver cannot meet in person with a member of the study team to sign the informed consent, the study coordinator will verbally consent the subject. The member of the study team will use the verbal consent script, then sign and date it using either wet-ink or an Adobe Certified signature to confirm that s/he followed the script and the subject agreed to participate in the study. Following the completion of verbal consent with the subject, the member of the study team will mail or email the subject a study information sheet that summarizes what the study entails and the subject’s involvement in it.

5.1.3. Baseline Measures and Study Procedures: The baseline measures will then be performed and

study procedures will occur. The patient must be determined to have decision-making capacity to provide informed consent by their treating oncologist.

5.1.4. Human Subject Protection: Ethical standards for human subjects will be strictly followed in accordance with the University of Rochester Research Subject Review Board Investigator Guidance policy and the University of Rochester Policy on Enrollment of Adult Decisionally Incapacitated Research Subjects and Permission of Authorized Representatives.

5.1.5. Participation: Current, state, federal, and institutional regulations concerning informed consent will be followed. Participation in this study is voluntary. Participants are free not to take part or to withdraw at any time, for whatever reason, without risking loss of present or future care they would otherwise expect to receive. In the event that a patient does withdraw from the study, the information they have already provided will be kept in a confidential manner. Participants may discontinue participation in the study at any time if they decide they do not wish to take part any longer. Participants may be withdrawn from the study by research personnel if it is deemed in their best interest to no longer participate.

5.1.6. Duration: Patients who consent to the study will be in this study for five months. Patients will be consented to actively participate, receive phone calls or meet with the research study team for up to 5 months after their initial workshop visit. The research team may contact patients in the future to gain further information first hand regarding patients' overall health and treatment. Dr. Magnuson may decide to take patients off the study without their consent if the study is stopped. Additionally, patient data will be kept for a period of 10 years at URM, even after the study is closed or a patient passes away. It will be maintained in a locked database with password access only (See Section 8).

6.0 REGISTRATION AND RANDOMIZATION

6.1. Registration:

To register a participant who meets the eligibility criteria and who has signed the informed consent document, study staff will enter the information outlined in section 6.2 in the OnCore database.

6.2. Information Requested at Registration:

- 6.2.1** First name
- 6.2.2** Last name
- 6.2.3** eMRN
- 6.2.4** Birth Date
- 6.2.5** Gender
- 6.2.6** Race
- 6.2.7.** Ethnicity

6.3. Initial Assessment:

After consent procedures are completed, the patient, with the help of the study coordinator, will complete a baseline assessment (See section 7).

6.4 Randomization Procedures:

The two intervention arms are as follows:

Arm 1= MAAT-G intervention

Arm 2 = Supportive therapy (time and attention control)

A computer-generated random numbers table, stratified by stage (local [stage I-III] and advanced [stage IV]) with equal probability of block size 2 or 4 will be used to assign participants to one of the two treatment arms. The randomization will assign participants to the two arms in the ratio 1:1. The random numbers tables will be generated centrally using R software. A total enrollment of 85 participants is planned to accommodate for potential 15% attrition, with at least 35 participants in each treatment arm.

Subjects can be registered prior to obtaining baseline measures however, subjects will not be aware of which arm they are randomized to until after the baseline assessment. After registered, they will be scheduled to undergo baseline measures. At the end of the visit for baseline assessment, they will be randomized.

7.0 TREATMENT PROTOCOL

7.1 Measures:

Patient measures will include demographics, cognitive, psychological, and functional independence measures. The battery was selected based upon our experience in prior studies.^{1,26,50,51} Based upon experience in prior studies, we estimate the cognitive evaluation will take approximately 60 minutes to complete^{1,3} and the demographics, psychological and functional independence measures will take approximately 20 minutes.

Demographics: Patient and caregiver demographics will be collected, including age, gender, race, ethnicity, marital status, education and socio-economic status will be captured. Cancer and treatment variables, comorbidities, and medications list will be collected from the medical record by study staff.

Cognitive Evaluation will include: 1) FACT-Cog⁵², a validated patient reported outcome measure created to assess cognitive challenges identified by patients with cancer; 2) Brief Test of Adult Cognition by Telephone⁷⁹ (BTACT), a slightly modified version that assesses multiple dimensions central for effective functioning across adulthood; 3) Cambridge Neuropsychological Test Automated Battery (CANTAB) delayed match to sample test⁵³ (DMS), Rapid Visual Information Processing (RVP), and Paired Associates Learning (PAL), validated, computerized tests that assess short- term visual/spatial memory, sustained attention, and visual memory/new learning; 4) Controlled Oral Word Association (COWA)⁵⁴, a measure of verbal fluency evaluating expressive language and executive function; and 5) Hopkins Verbal Learning Test-Revised (HVLTR)⁵⁵, a validated test of verbal learning and memory. All measures are “paper and pencil”, except for the CANTAB (computer-based assessments that, due to COVID-19, will be administered virtually by collecting patients’ emails and sending a web- based link). COWA, HVLTR, and BTACT require the study coordinator to administer the tests; they can be administered virtually so study coordinator will schedule a telephone or televideo meeting with the patient at the corresponding time points, as needed.

Psychological Assessment: will include Geriatric Depression Screen (GDS)⁵⁷, Generalized Anxiety and Depression (GAD-7)⁵⁸, and Intolerance of Uncertainty Scale-Short Form (IUS-12). IUS-12 will be administered by the study coordinator over the phone or via televideo (Zoom application) at the appropriate time points.

Functional Independence: IADLs will be measured⁵⁹. IADL will be administered by the study coordinator over the phone or via televideo (Zoom application) at the appropriate time points.

Phase II semi-structured interview questions for patients and caregivers will focus on perceptions of cognitive change and potential benefit of intervention sessions.

7.1 Study Procedures:

Baseline: Following informed consent, patients will undergo Time Point (TP) 1 assessment. Patients will be provided with a data-enabled tablet with HIPAA-compliant video-conferencing application and instructed on its use, participant workbook (for MAAT-G intervention participants only), and tablet instruction manual. The study coordinator will give the patients a drawstring bag to hold all study materials given at TP1. At the time of enrollment, the study coordinator will assign each patient a unique meeting ID number within the tablet instruction manual. This meeting ID number allows each patient to log on to the video-conferencing application and speak to trained clinician (e.g. the MAAT-G Interventionist). Study coordinators will train and support patients on the use of the tablet and video conferencing application. No data is being stored on the tablet itself. If patients consent to have sessions recorded, this will be done through the HIPAA-compliant Zoom software application. If participants do not have access to wireless internet, the tablet will be equipped with a data package for participant use for the purposes of this study. At completion of the study, patients will return the tablet to the study coordinator. If the tablet is lost or stolen during the study, no PHI will be stored on the tablet and thus would not be accessible. If the tablet is broken during the course of the study, we will provide participants with another tablet for use during the study period. The participant would contact the study coordinator with any concerns or problems with using the tablet, contact information will be provided during training on tablet use.

Intervention Period: The intervention period is 10-12 weeks; 10 weekly workshops will be delivered through video-conferencing on the tablet. Workshops will be audio-recorded for fidelity review. (See section 7.2)

Follow-up: Within 1 day to 4 weeks of intervention completion (approximately week 10-14), patients will undergo TP2 assessment.

Patient assessments will be performed by trained study coordinators. As a safety precaution due to COVID-19, patients may take surveys home for completion (e.g. demographics) and then mail back to study team in order to minimize the amount of in-person contact between coordinators and patients; the method of completing surveys at home has been successful in prior studies with good retention.^{43,48} However, to encourage the completion of the surveys, the study coordinator will schedule a telephone or televideo meeting with the patient, as needed, to ensure patients' questions concerning the surveys are addressed. Study coordinators will score assessments and transcribe results into a database. Audio- recordings will be deleted following transcription.

Semi-structured interviews will be conducted by a trained study coordinator who is not responsible for any other component of the study. Interviews will be conducted with patients and if consented, will include caregivers. As a safety precaution due to COVID-19, the interviews with the patients and caregivers will be conducted over the phone or over Zoom televideoconferencing application. These audio-recorded interviews will be conducted after completion of the intervention.

Location: Participation in workshops will take place through video-conferencing. Participants will be encouraged to participate from their home or other private location. Due to COVID-19, the Department of Psychology is conducting clinical visits from their clinical office and home office locations until further notice. Wherever the location may be, the trained clinician (e.g. psychologist psychology post-doctoral

fellow, psychology intern, or Research Registered Nurse [RN] trained in MAAT-G) who is conducting the interventions will ensure privacy in a private room with a closed door. Participants will be provided with a HIPAA compliant tablet to use for participation in the intervention activities and the intervention will be delivered using HIPAA compliant video-conferencing technology provided by the University of Rochester. The coordinator will be in touch with patients by phone throughout the length of the study, serving as a liaison between patient and trained clinician MAAT-G Interventionist. Coordinator will help organize the scheduling/rescheduling of workshop sessions and will be available for any patient questions.

7.2. Study Interventions

7.2a. MAAT-G Intervention

The MAAT-G intervention will be delivered by a trained clinician (also described as MAAT-G Interventionist and includes psychologist, psychology post-doctoral fellow, psychology intern, or Research RN trained in MAAT-G) at the University of Rochester Medical Center. The intervention will be delivered through televideoconferencing and participants will be provided a tablet equipped with a HIPAA compliant televideoconferencing application to use for the MAAT-G workshop sessions. We will use the University of Rochester Zoom application which is HIPAA compliant. A tablet instruction manual will be given to patients to help guide them through how to use a tablet and how to navigate the Zoom application. A unique meeting ID number will be given to each patient to log in to the Zoom application. If participants do not have access to wireless internet, the tablet will be equipped with a data package for participant use for the purposes of this study.

Participants will also be provided a workbook for skills practice in between workshop sessions. A summary of workshop content is provided in table 2 below.

During Workshop #2, the study coordinator or trained MAAT-G Interventionist will provide patients a link to a Vimeo video. The coordinator will email the link to patients a couple days before Workshop #2. The Vimeo video has been created by the study team and talks patients through how to remain relaxed before stressful events occur. Study patients will be able to access the video without providing any personal information to the website.

Table 2: MAAT-G workshop content WORKS HOP VISIT:	Content/Strategies:
1	<ul style="list-style-type: none"> • Introduction to MAAT • Self-Awareness and monitoring of memory problems
2	<ul style="list-style-type: none"> • Progressive Muscle Relaxation • Quick Relaxation
3	<ul style="list-style-type: none"> • Self-Instructional Training • Verbal and silent rehearsal
4	1. Cognitive restructuring
5	2. Keeping a schedule <ul style="list-style-type: none"> • Memory routines
6	1. External cueing <ul style="list-style-type: none"> • Distraction reduction
7	1. Activity scheduling and pacing 2. Active listening

8	1. Fatigue management 2. Sleep improvement
9	<ul style="list-style-type: none"> • Visualization strategies
10	<ul style="list-style-type: none"> • Tying it all together

7.2b. Supportive care control condition

Supportive Therapy (ST) is a “behavioral placebo” and controls for non-specific psychotherapeutic factors of the clinician-subject relationship, such as empathy and support, but does not provide active cognitive training. ST utilizes reflective listening to help deepen awareness of participants’ emotional experience. ST was used as the control condition for a prior MAAT study.⁷¹ A clinician manual for ST has been developed.⁷¹ Timing and duration of ST sessions will mirror the intervention, and will consist of 10 weekly sessions, 30 to 45 minutes each, delivered by a trained clinician (e.g. psychologist, psychology post-doctoral fellow, psychology intern, or Research RN) via video-conferencing.

We will offer subjects who are randomized to the Supportive Therapy (ST) group the opportunity to receive the MAAT-G Intervention after their completion of the 10 ST sessions and the post-intervention follow-up time point procedures. We will not administer an additional evaluation during this time period if patients elect to proceed with MAAT-G after completing study procedures (e.g. no further time points for followup of cognition or survey measures). If patients do elect to continue with this, we will continue to monitor for potential adverse events that are related to the behavioral intervention (see Data Safety Monitoring section below). Participants electing to continue and receive MAAT-G after completing study procedures can discontinue at any time. If subjects decide to get the MAAT-G intervention, they do not need to complete all 10 sessions or within a certain timeframe. We will collect data on the number of ST subjects who chose to do the additional MAAT-G Intervention and the number of sessions completed. The intent of allowing patients randomized to ST to continue and receive MAAT-G after completion of study procedures is to facilitate retention.

The University Advarra system will be used per WCI policy for study reimbursement for \$30 per time point/workshop. The templated RSRB information for Advarra will be used for information for patients for use of the gift card system. The study team will collect W-9 to send to University Accounts Processing for study payment documentation and send to accountspayable@finance.rochester.edu. Following this, the participant W-9 will be shredded. W-9 information will not be kept by the study team.

7.3. Potential risks:

A participant may become more aware of any attention or memory problem they are experiencing as a result of participation in this study, potentially increasing psychological stress. While this is unlikely to provoke significant problems, the PI (Dr. Magnuson) will be available for evaluation and referral to appropriate behavioral care if needed.

Risks to privacy using telehealth and telecommunications are a potential concern. We also recognize that while encryption of videoconferencing makes breeches of private information unlikely, not all risks to privacy can be completely eliminated. We will inform all participants using the telehealth equipment of this.

7.4. Potential benefits:

There may be no direct benefits to participation in this study. However, the study will provide useful information about systemic cancer therapy-associated cognitive problems for older adults and strategies for helping patients cope with memory and attention problems.

8.0 DATA MANAGEMENT

8.1. Data Handling and Statistical Considerations:

8.1.1. The same protocols and procedures for data quality and control that are readily used for prior studies conducted with the Geriatric Oncology Research Group and currently being overseen by our office. Data will be entered into REDCap (see section 8.3.5 below).

8.1.2. After entering into REDCap, data are audited visually for errors. R, SPSS and SAS will be used for the statistical analyses. Unless otherwise stated, all statistical tests will be performed at the two-tailed 5% level of significance. Likewise, 95% confidence intervals will be constructed for the estimation of effects.

8.1.3. The assumptions underlying all statistical analyses will be thoroughly checked using appropriate graphical and numerical methods.^{65,66} In case of violations of distribution assumptions such as normality, appropriate nonparametric methods will be attempted.^{67,68} If outliers or influential data are detected, the accuracy of the data will be investigated. If no errors are found, analyses may be repeated after removing these cases to evaluate their impact on the results. However, the final analyses will include these data points.


8.2. Data Analysis and Sample Size:

Data Analytic Plan:

Power Analysis and Sample Size Consideration: The effect size for MAAT-G concurrent with systemic cancer therapy in older adults is not known; the purpose of this study is to gather preliminary efficacy data on perceived cognition (FACT-Cog). MAAT has demonstrated a medium effect size ($d = 0.52$) on FACT-Cog in younger cancer survivors. Using analysis of covariance (ANCOVA) design and pre-post correlation of 0.5, a sample size of $n=35$ evaluable patients per group will provide 80% power to detect an effect size of 0.52 at the significance level of 0.10 (**Figure 1**). Assuming 15% attrition, we will enroll 85 patients.

Quantitative Data Analysis: Underlying assumptions to all statistical analyses will be checked using appropriate graphical and numerical methods.⁷² In the case of serious violation of assumptions, appropriate transformations or nonparametric methods will be used.^{73,74} If outlying observations are encountered, data will be checked. If no errors are found, we will conduct analyses with and without the outlying data and compare results. Bivariate associations between treatment group and participant variables (demographics, cancer and treatment characteristics, baseline assessment of outcome measures) will be examined to assess possible imbalance between arms. Since this is a pilot study, will use significance level=0.10 to avoid false negative results, and decrease the risk of abandoning a promising intervention.^{75,76}

Analysis of the primary outcome: To assess the impact of the intervention on patient-reported cognition (FACT-Cog), we will employ the analysis of covariance (ANCOVA). The model will consist of post-FACT-Cog as the outcome and include the arm as the main effect and pre-FACT-Cog as a covariate. We will evaluate the interaction between pre-FACT-cog and the arm. We will adjust for baseline covariates in case that imbalance between arms was detected, and baseline and change in psychological measure (GDS and GAD-7). All non-significant covariates will be removed from the model.



Analysis of secondary and exploratory outcomes: The effect of MAAT-G on objective cognition (CVLT-R, TBANS, CANTAB, COWA, HVLT-R, TMT A/B), functional independence (IADL) and stress response (cortisol) will be assessed with the same strategy as for the primary outcome.

As above, a sample size of 85 patients is planned based upon anticipated attrition rates. If attrition of patients occurs at a higher proportion than anticipated during the trial conduct, we will conduct an interim data analysis check to assess for need in adjusting sample size.

Phase II Qualitative Data Analysis: Semi-structured interviews will be prepared and coded similar to Phase Ib. Potential themes from Phase II interviews include experiences of cognitive failure and perceived timing and mode of onset of symptoms, changes in functional independence, perception of how the intervention (either MAAT-G or ST) influenced symptoms and experience, and experiences with the adaptive behavioral or compensatory techniques used.

Mixed Methods Integration: Qualitative and quantitative data will be integrated (**Table 3**) to enhance our understanding of the participant experience with MAAT-G and explore potential benefits beyond what is captured in quantitative tools. Our primary outcome, FACT-Cog, is a validated tool to measure perceived cognition and was developed through qualitative methods. However, the average age of patients involved was 59.6 years old,⁷⁷ and it is possible the FACT-Cog does not capture cognitive experiences that are unique to older adults. Quantitative data will be analyzed first to determine longitudinal change in perceived cognition, and then integrated with qualitative data to evaluate if qualitative themes differ between patients who experience longitudinal improvement in perceived cognition versus those with longitudinal decline as well as difference in themes between study arms. Data will be organized using MAXQDA joint displays.⁷⁸

Table 3: Integration plan:

Aim Phase II	Data Collection Procedures	Analysis Procedures	Point of Integration	Example of Integration Enhancing the Detection of MAAT-G Benefits
Estimate the effect of MAAT on FACT-Cog, objective measures of cognition and functional independence and explore through semi-structured qualitative interviews, the patient and caregiver experience with MAAT-G and perception of how MAAT-G influences daily functioning and perceived benefits.	<ul style="list-style-type: none"> Cognitive Assessment (<i>Quant</i>): <u>Perceived</u>: FACT-Cog <u>Objective</u>: Neuro-psychological assessment battery Functional Independence (<i>Quant</i>): IADL Semi-structured interviews (<i>Qual</i>) 	<ul style="list-style-type: none"> Descriptive statistics, t-tests, chi-square tests, logistic regression Theme analysis guided by Phenomenology 	<p><i>Merging</i>: Qual and Quant are brought together for analysis</p> <p><i>Purpose</i>: To use qual data to help explain the quant outcomes; to understand in more depth how the conceptual model mechanism worked; to assess the context when comparisons of outcomes are made with baseline data.</p>	We will compare themes between patients who report longitudinal improvement in perceived cognition versus those who report longitudinal decline and we will compare themes between study arms. (e.g. patients with longitudinal improvement in perceived cognition or those receiving MAAT-G may report a greater ability to manage the complex schedule of cancer treatments or a greater ability to participate in social roles such as caregiving for a spouse or volunteer activities).

8.3. Records to be Kept:

8.3.1. Data Collection Table:

SCHEDULE OF DATA COLLECTION

FORM	Baseline	Post-Intervention
On Study Data (Patient and caregiver demographic information and clinical data)	X	
FACT-COG	X	X
CANTAB	X	X
BTACT	X	X
COWA	X	X
HVLT-R	X	X
	X	X
GAD-7	X	X
IADL Survey	X	X
IUS-12	X	X

8.3.2 All hardcopy research records will be stored onsite in the University of Rochester Medical Center, in locked research files at the James P. Wilmot Cancer Center. The Cancer Center is secured with electronic key cards. Offices within the Cancer Center are again secured by key and data is kept in locked file cabinets. Electronic research records are stored on the University of Rochester Medical Center's password secured and firewall protected networks. These are the same methods of security used for patient medical records. All study data will be kept for a period of 10 years after the study and all reports and publications are complete.

8.3.3 All recorded data, such as the audio-recorded interviews/transcripts and Zoom workshop sessions, will be stored on the UR Box drive to assess fidelity of intervention delivery. Within the Box drive, data will be stored in a password protected folder with access restricted to the PI and a subset of study team members. All personal identifiers will be deleted (e.g. de-identified) from the transcriptions of the audio-recordings. Once data is uploaded to the secure server, the data will be deleted from the audio recorders.

8.3.4. All data collected for the current study will be used in post hoc analyses as appropriate. Data will not be used for future studies without prior consent of the patient. The patient's individual research record will not be shared with their treating physician, unless they provide consent or the patient's treating physician is a study physician, in which case they will have access to study data as a study co-investigator. Overall study results will be presented to participants, faculty and staff at the University of Rochester Medical Center after completion of the study. Study results will be presented at professional meetings and published.

8.3.5. The study coordinator will assign a numerical study ID to each participant once they have signed the consent form. All study forms and questionnaires will use this number and the participant's first, middle, and last initials as identifiers, to ensure data integrity. Other identifying information will not exist on these forms. A complete list of study participants with study ID, name, and contact information will be maintained separately. This linkage information will only be accessible to the study coordinator, study investigators, and the individuals responsible for maintaining the database.

8.3.6. Additionally, the data can be collected and managed by the research teams at University of Rochester Medical Center using REDCap¹⁶⁷ electronic data capture tools hosted at URM.

8.3.6a. URM provides the following information on the REDCap program: "Vanderbilt University, in collaboration with a consortium of institutional partners, has developed a software toolset and workflow methodology for electronic collection and management of research and clinical trial data, called REDCap (Research Electronic Data Capture). The REDCap system is a secure, web-based application that is flexible enough to be used for a variety of types of research. It provides an intuitive interface for users to enter data and real time validation rules (with automated data type and range checks) at the time of data entry. REDCap offers easy data manipulation with audit trails and functionality for reporting, monitoring and querying patient records, as well as an automated export mechanism to common statistical packages (SPSS, SAS, Stata, R/S-Plus). Through the REDCap Consortium, Vanderbilt has disseminated REDCap for use around the world.

Currently, over 240 academic and non-profit consortium partners on six continents with over 26,000 research end-users use REDCap”¹⁶⁸.

8.3.56. According to the Clinical and Translational Science Institute (CTSI), REDCap is supported with the following means. “The *CTSI Informatics Core*, a unit of the *SMD Academic Information Technology (AIT) Group*, will serve as a central facilitator for data processing and management. REDCap data collection projects rely on a thorough study-specific data dictionary defined in an iterative self-documenting process by all members of the research team, with planning assistance from the *AIT-CTSI Informatics Core*. The iterative development and testing process results in a well-planned data collection strategy for individual studies”¹⁶⁸.

8.3.6c. The CTSI states that regarding security, “REDCap servers are housed in a local data center at the University of Rochester and all web-based information transmission is encrypted. REDCap was developed in a manner consistent with HIPAA security requirements and is recommended to University of Rochester researchers by the URM Research Privacy Officer and Office for Human Subject Protection.”¹⁶⁸

9.0 DATA SAFETY AND MONITORING

This protocol should be considered low risk as the intervention is a cognitive behavioral therapy (CBT)-based intervention. CBT-based treatments are utilized in routine clinical care for use with community dwelling older adults. This study is designed to see if MAAT, a CBT-based intervention, is feasible to deliver to older adults receiving systemic cancer therapy for breast cancer and can improve cognitive outcomes for this population.

9.1. Adverse Event Reporting Requirements:

9.1.1. Adverse events will be reported using the URCC Adverse Event form and/or as required by the Cancer Center Clinical Trials Office.

9.1.2. Adverse events will be reported in accordance with the following guidelines. We will not report adverse events if it is not required per the guidelines.

	Grade 1	Grade 2			Grade 3				Grade 4		Grade 5	
	Unexpe cted and	Unexpected		Expect	Unexpected		Expected		Unexpe	Expect	Unexpect	Expect
		with hospit	witho ut		with hospit	witho ut	with hospit	witho ut				
Unrelat ed Unlikel	Not Require d	Not Requir ed	Not Requir ed	Not Requir ed	Not Requir ed	Not Requir ed	Not Requir ed	Not Requir ed	10 Calenda r Days	Not Requir ed	10 Calendar Days	10 Calend ar Days
Possibl e Probabl	Not Require d	10 Calen dar	Not Requir ed	Not Requir ed	10 Calen dar	10 Calen dar	Not Requir ed	Not Requir ed	24- Hour; 5	10 Calend ar Days	24-Hour; 5 Calendar	10 Calend ar Days

Hospitalization is defined as initial hospitalization or prolongation of hospitalization for ≥ 24 hours, **due to adverse event**.

9.1.3. Adverse event reports will be submitted in one of the following ways:

(1) By email: (pdf)

(2) By mail:

(3) By fax:

9.1.4. An unexpected adverse event is defined as any adverse experience, the specificity or severity of which is not consistent with the risk information. This is a low risk study as interventions have been shown to improve outcomes of community-dwelling older adults.

9.1.5. A serious event refers to any event in which the outcome results in any of the following: death, a life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability, incapacity, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered a serious adverse drug experience when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. We anticipate that any serious events will be related to standard of care cancer treatment and not due to the MAAT-G intervention, which is designed to improve outcomes and focus on cognitive side effects of cancer treatment. To reiterate, only adverse events attributed to the behavioral intervention will be captured and reported.

9.1.6. Adverse events will be reported in accordance with institutional policies (University of Rochester, Research Subject Review Board, local IRB, URCC CCOP, CTO, and DSMB) as per their requirements.

9.1.7. For patients randomized to ST arm who elect to receive MAAT-G after completion of all study procedures, we will continue to monitor for AE during the time period that they are continuing. To reiterate, only adverse events attributed to the behavioral intervention will be captured and reported.

9.2. Data Safety Monitoring:

9.2.1. All adverse events requiring reporting will be submitted to the current Project Coordinator as described in Section 9.1. Serious adverse event reports will be forwarded to the study chair and the Data Safety and Monitoring Committee (DSMC). Adverse events are entered into a protocol-specific spreadsheet.

9.2.2. Adverse event rates are monitored utilizing the spreadsheet. If a serious adverse event is reported frequently, the study chair will conduct a detailed review. The DSMC Committee Chair will be notified and will determine if further action is required.

9.2.3. The Data Safety Monitoring Committee (DSMC) will review study progress and cumulative reports of adverse events at annual meetings and as needed. An overall assessment of accrual and adverse events will enable the committee members to assess whether significant benefits or risks are occurring that would warrant study closure.

9.2.4. The URCC will notify the other sites immediately of any serious safety concerns identified by the DSMC.

10.0 REFERENCES

1. Janelins MC, Heckler CE, Peppone LJ, et al. Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2017;35:506-14.
2. Janelins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. *Int Rev Psychiatry* 2014;26:102-13.
3. Janelins MC, Heckler CE, Peppone LJ, et al. Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study. *J Clin Oncol* 2018;JCO2018786624.
4. Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28:4434-40.
5. Cruzado JA, Lopez-Santiago S, Martinez-Marin V, Jose-Moreno G, Custodio AB, Feliu J. Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients. *Support Care Cancer* 2014;22:1815-23.
6. Jones D, Vichaya EG, Wang XS, Sailors MH, Cleeland CS, Wefel JS. Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. *Cancer* 2013;119:4188-95.
7. Magnuson A, Mohile S, Janelins M. Cognition and Cognitive Impairment in Older Adults with Cancer. *Curr Geriatr Rep* 2016;5:213-9.
8. Mandelblatt JS, Small BJ, Luta G, et al. Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2018;JCO1800140.
9. Hurria A, Goldfarb S, Rosen C, et al. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. *Breast Cancer Res Treat* 2006;98:343-8.
10. Hurria A, Rosen C, Hudis C, et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. *J Am Geriatr Soc* 2006;54:925-31.
11. Ferguson RJ, McDonald BC, Rocque MA, et al. Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. *Psychooncology* 2012;21:176-86.
12. Heflin LH, Meyerowitz BE, Hall P, et al. Cancer as a risk factor for long-term cognitive deficits and dementia. *J Natl Cancer Inst* 2005;97:854-6.
13. Yamada TH, Denburg NL, Beglinger LJ, Schultz SK. Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy. *J Neuropsychiatry Clin Neurosci* 2010;22:48-54.
14. Selamat MH, Loh SY, Mackenzie L, Vardy J. Chemobrain experienced by breast cancer survivors: a meta-ethnography study investigating research and care implications. *PloS one* 2014;9:e108002.
15. Janelins MC, Kohli S, Mohile SG, Usuki K, Ahles TA, Morrow GR. An update on cancer- and chemotherapy-related cognitive dysfunction: current status. *Semin Oncol* 2011;38:431-8.
16. Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. *J Clin Oncol* 2012;30:3675-86.
17. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. *Nat Rev Cancer* 2007;7:192-201.
18. Mandelblatt JS, Stern RA, Luta G, et al. Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity? *J Clin Oncol* 2014;32:1909-18.

19. Andreotti C, Root JC, Ahles TA, McEwen BS, Compas BE. Cancer, coping, and cognition: a model for the role of stress reactivity in cancer-related cognitive decline. *Psychooncology* 2015;24:617-23.
20. Arndt J, Das E, Schagen SB, Reid-Arndt SA, Cameron LD, Ahles TA. Broadening the cancer and cognition landscape: the role of self-regulatory challenges. *Psychooncology* 2014;23:1-8.
21. Mohile S, Dale W, Magnuson A, Kamath N, Hurria A. Research priorities in geriatric oncology for 2013 and beyond. *Cancer Forum* 2013;37:216-21.
22. Mohile SG, Hurria A, Cohen HJ, et al. Improving the quality of survivorship for older adults with cancer. *Cancer* 2016;122:2459-568.
23. Magnuson A, Allore H, Cohen HJ, et al. Geriatric assessment with management in cancer care: Current evidence and potential mechanisms for future research. *Journal of geriatric oncology* 2016;7:242-8.
24. Loh KP, Janelins MC, Mohile SG, et al. Chemotherapy-related cognitive impairment in older patients with cancer. *Journal of geriatric oncology* 2016;7:270-80.
25. Karuturi M, Wong ML, Hsu T, et al. Understanding cognition in older patients with cancer. *J Geriatr Oncol* 2016;7:258-69.
26. Ferguson RJ, Sigmon ST, Pritchard AJ, et al. A randomized trial of videoconference-delivered cognitive behavioral therapy for survivors of breast cancer with self-reported cognitive dysfunction. *Cancer* 2016;122:1782-91.
27. Ferguson RJ, Ahles TA, Saykin AJ, et al. Cognitive-behavioral management of chemotherapy-related cognitive change. *Psychooncology* 2007;16:772-7.
28. Kucherer S, Ferguson RJ. Cognitive behavioral therapy for cancer-related cognitive dysfunction. *Curr Opin Support Palliat Care* 2017;11:46-51.
29. Lange M, Heutte N, Rigal O, et al. Decline in Cognitive Function in Older Adults With Early-Stage Breast Cancer After Adjuvant Treatment. *Oncologist* 2016;21:1337-48.
30. Lange M, Heutte N, Noal S, et al. Cognitive Changes After Adjuvant Treatment in Older Adults with Early-Stage Breast Cancer. *Oncologist* 2018.
31. McGuire LC, Ford ES, Ajani UA. Cognitive functioning as a predictor of functional disability in later life. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry* 2006;14:36-42.
32. Mandelblatt JS, Jacobsen PB, Ahles T. Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors. *J Clin Oncol* 2014;32:2617-26.
33. Mandelblatt JS, Clapp JD, Luta G, et al. Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance). *Cancer* 2016.
34. Hurria A, Soto-Perez-de-Celis E, Allred JB, et al. Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer. *J Am Geriatr Soc* 2018.
35. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. *Jama* 2004;291:2720-6.
36. Wildiers H, Mauer M, Pallis A, et al. End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2013;31:3711-8.
37. Hurria A. Incorporation of geriatric principles in oncology clinical trials. *J Clin Oncol* 2007;25:5350-1.
38. Hurria A, Mohile SG, Dale W. Research priorities in geriatric oncology: addressing the needs of an aging population. *Journal of the National Comprehensive Cancer Network : JNCCN* 2012;10:286-8.

39. Magnuson A AH, Cohen HJ, Mohile SG, Williams GR, Chapman A, Extermann M, Olin RL, Targia V, Mackenzie A, Holmes HM, Hurria A. Geriatric Assessment with Management in Cancer Care: Current Evidence and Potential Mechanisms for Future Research. *Journal of geriatric oncology* 2016.
40. Solberg Nes L, Ehlers SL, Patten CA, Gastineau DA. Self-regulatory fatigue in hematologic malignancies: impact on quality of life, coping, and adherence to medical recommendations. *Int J Behav Med* 2013;20:13-21.
41. Muraven M, Tice DM, Baumeister RF. Self-control as limited resource: regulatory depletion patterns. *J Pers Soc Psychol* 1998;74:774-89.
42. Schmeichel BJ. Attention control, memory updating, and emotion regulation temporarily reduce the capacity for executive control. *J Exp Psychol Gen* 2007;136:241-55.
43. Mohile SG ER, Hurria A, Heckler CE, Duberstein P, Canin BE, Gilmore N, Wells M, Xu H, Culakova E, Lowenstein LM, Flannery MA, Magnuson A, Loh LP, Mustian KM, Hopkins JO, Liu J, Melnyk N Morrow GR, Dale W. . Improving Communication With Older Patients With Cancer Using Geriatric Assessment (GA): A University of Rochester NCI Community Oncology Research Program (NCORP) Cluster Randomized Controlled Trial (CRCT). *American Society Clinical Oncology*; 2018; Chicago, IL: *Journal of Clinical Oncology*.
44. Magnuson A, Lei L, Janelsins MC, et al. The impact of a positive cognitive impairment screen on conversations between patients, caregivers, and oncologists: A UR NCORP randomized study. *Journal of Clinical Oncology* 2018;36:10048-.
45. Magnuson A LL, Janelsins MC, Culakova E, Lin FV, Gilles M, Hurria AT, Dale W, Duberstein P, Wittink M, Wells M, Gilmore N, Hamel L, O'rourke MA, Onitilo AA, Bradley TP, Whitehead MI, Mohile SG. The Impact of a Positive Cognitive Impairment Screen on Conversations Between Patients, Caregivers, and Oncologists: A UR NCORP Randomized Study. *American Society of Clinical Oncology*; 2018; Chicago, IL.
46. Magnuson A LL, Janelsins M, Culakova E, Lin FV, Ferguson R, Gilles M, Hurria A, Dale W, Duberstein P, Wittink M, Bautista J, Plumb S, Berenberg J, Vogel VG, Philip T, Sedenquist M, Mohile S. . Discussions about cognition between older patients, caregivers, and oncologists: A University of Rochester NCORP randomized study. *International Society of Geriatric Oncology*; 2018 To be presented November 2018.; Amsterdam, The Netherlands.
47. Magnuson A, Mohile SG, Lei L, et al. Longitudinal trajectory of frailty and related factors in 376 breast cancer patients aged 50+ compared to controls. *Journal of Clinical Oncology* 2017;35:e21532-e.
48. Magnuson A, Lemelman T, Pandya C, et al. Geriatric assessment with management intervention in older adults with cancer: a randomized pilot study. *Support Care Cancer* 2018;26:605-13.
49. Magnuson A PC, Lemelman T, Goodman M, Janelsins M, Mohile S. Longitudinal change in clock drawing with cancer treatment and factors associated with change in score. *American Geriatrics Society*; 2016; Orlando, FL.
50. Janelsins MC HC, Peppone LJ, Kame C, Mustian K, Mohile SG, Magnuson A, Kleckner IR, Guido JJ, Young K, Conlin AK, Weiselberg LR, Mitchell JW, Ambrosone CB, Ahles TA, Morrow GR. Longitudinal Trajectory of Cancer-Related Cognitive Impairment Up To Six Months Post-Chemotherapy: A Nationwide NCORP Study in 945 Breast Cancer Patients and Non-Cancer Controls. *American Society of Clinical Oncology*; 2016; Chicago, IL.
51. Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. *Cancer* 2005;104:1998-2005.
52. Wagner LI, Berg SR, Gandhi M, et al. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). *Support Care Cancer* 2013;21:1033-41.

53. Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. *Dementia* 1994;5:266-81.
54. Ruff RM, Light RH, Parker SB, Levin HS. Benton Controlled Oral Word Association Test: reliability and updated norms. *Arch Clin Neuropsychol* 1996;11:329-38.
55. Shapiro AM, Benedict RH, Schretlen D, Brandt J. Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. *Clin Neuropsychol* 1999;13:348-58.
56. Levine AJ, Miller EN, Becker JT, Selnes OA, Cohen BA. Normative data for determining significance of test-retest differences on eight common neuropsychological instruments. *Clin Neuropsychol* 2004;18:373-84.
57. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. *J Psychiatr Res* 1982;17:37-49.
58. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* 2006;166:1092-7.
59. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies Of Illness In The Aged. The Index Of Adl: A Standardized Measure Of Biological And Psychosocial Function. *Jama* 1963;185:914-9.
60. Brown W, 3rd, Yen PY, Rojas M, Schnall R. Assessment of the Health IT Usability Evaluation Model (Health-ITUEM) for evaluating mobile health (mHealth) technology. *J Biomed Inform* 2013;46:1080-7.
61. Schnall R, Cho H, Liu J. Health Information Technology Usability Evaluation Scale (Health-ITUES) for Usability Assessment of Mobile Health Technology: Validation Study. *JMIR Mhealth Uhealth* 2018;6:e4.
62. Kushniruk AW, Patel VL, Cimino JJ. Usability testing in medical informatics: cognitive approaches to evaluation of information systems and user interfaces. *Proc AMIA Annu Fall Symp* 1997:218-22.
63. Kushniruk A. Evaluation in the design of health information systems: application of approaches emerging from usability engineering. *Comput Biol Med* 2002;32:141-9.
64. Currie SL, McGrath PJ, Day V. Development and usability of an online CBT program for symptoms of moderate depression, anxiety, and stress in post-secondary students. *Comput Hum Behav* 2010;26:1419-26.
65. Atkinson A, ed. *Plots, Transformation, and Regression*. Oxford: Oxford University Press; 1985.
66. Cook R, Weisberg S, eds. *London: Chapman and Hall*;1982.
67. Conover W, Iman R. Rank transformations as a bridge between parametric and nonparametric statistics. *American Statistics* 1981;35:124-33.
68. Conover W, Iman R. On some alternative procedures using ranks for the analysis of experimental designs. *Comm Statist A* 1976;5:1349-68.
69. Little R, Yau L. Intent-to-treat analysis for longitudinal studies with drop-outs. *Biometrics* 1996;52:1324-33.
70. Guetterman TC, Feters MD, Creswell JW. Integrating Quantitative and Qualitative Results in Health Science Mixed Methods Research Through Joint Displays. *Annals of family medicine* 2015;13:554-61.
71. Ferguson RJ, Sigmon ST, Pritchard AJ, et al. A randomized trial of videoconference-delivered cognitive behavioral therapy for survivors of breast cancer with self-reported cognitive dysfunction. *Cancer* 2016;122:1782-91.
72. Cook RD, Weisberg S. *Residuals and Influence in Regression*. London: Chapman and Hall;1982.
73. Conover WJ, Iman RL. On some alternative procedures using ranks for the analysis of experimental designs. *Comm Statist A* 1976;5:1349-68.
74. Conover WJ, Iman RL. Rank transformations as a bridge between parametric and nonparametric statistics. *American Statist* 1981;35:124-33.

75. Kraemer HC, Mintz J, Noda A, Tinklenberg J, Yesavage JA. Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiat 2006;63:484-9.
76. Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 2005;23:7199-206.
77. Wagner L SJ, Butt Z, Lai J, Cella D. Measuring patient self-reported cognitive function: Development of the Functional Assessment of Cancer Therapy-Cognitive Function Instrument. J Sup Oncol 2009;7:W32-39.
78. Guetterman TC, Fetters MD, Creswell JW. Integrating Quantitative and Qualitative Results in Health Science Mixed Methods Research Through Joint Displays. Annals of family medicine 2015;13:554-61.
79. Lachman ME, Agrigoroaei S, Tun PA, Weaver SL. Monitoring Cognitive Functioning: Psychometric Properties of the Brief Test of Adult Cognition by Telephone. Assessment 2014;21(4),404-17.